<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian Journal of War and Public Health</title>
<title_fa>طب جانباز</title_fa>
<short_title>Iran J War Public Health</short_title>
<subject>Medical Sciences</subject>
<web_url>http://ijwph.ir</web_url>
<journal_hbi_system_id>153</journal_hbi_system_id>
<journal_hbi_system_user>ijwph</journal_hbi_system_user>
<journal_id_issn>2008-2622</journal_id_issn>
<journal_id_issn_online>2008-2630</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.58209/ijwph</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1400</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2021</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<volume>13</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Using Vascular Cell Adhesion Molecule-1 as a Biomarker for Detecting Progression of Different Types of Malignant Tumors</title>
	<subject_fa>سلامت جانبازان يا معلولان</subject_fa>
	<subject>Veterans or Handicapped Health</subject>
	<content_type_fa>گزارش مورد/سری</content_type_fa>
	<content_type>Case/Series Report</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;Aims: &lt;/strong&gt;Vascular cell adhesion molecule-1 is a transmembrane glycoprotein closely related to tumorigenicity as well as tumor metastasis. It is also a well-known candidate for detecting tumors as a very common consequence of war-related symptoms. This study was designed to investigate the probability of using a cancer biomarker (VCAM-1) as an indicator for the progression of breast, lung, and bladder cancers.&lt;br&gt;
&lt;strong&gt;Materials &amp; Methods: &lt;/strong&gt;This experimental study was conducted on 15 to 89 years-old patients who attended the Middle Euphrates cancer center and the breast disease clinic in AL-Sadder Medical City teaching hospital in Al-Najaf Province, Iraq, for a checkup from September 2020 to January 2021. Eighty-eight samples were selected by random sampling method; 22 patients for each breast, lung, and bladder cancer group and 22 healthy subjects as control. An Enzyme-Linked Immunosorbent Assay (ELISA) was used to evaluate the concentration of VCAM-1. Data were analyzed by one-way ANOVA and Tukey&amp;#39;s multiple comparison tests&lt;strong&gt;.&lt;/strong&gt;&lt;br&gt;
&lt;strong&gt;Findings:&lt;/strong&gt; The means&amp;plusmn;SE of VCAM-1 levels in control, breast, lung, and bladder cancer groups were 42.29&amp;plusmn;3.928ng/ml, 58.12&amp;plusmn;2.357ng/ml, 66.81&amp;plusmn;4.307ng/ml, and 82.85&amp;plusmn;7.292ng/ml, respectively. Serum VCAM-1 levels increased significantly in all groups compared to the control group (p&lt;0.05) except in breast cancer (p&gt;0.05). There was a significant difference only between breast and bladder cancer groups (p&lt;0.05).&lt;br&gt;
&lt;strong&gt;Conclusion:&lt;/strong&gt; The highest level of VCAM-1 is in the bladder cancer group; therefore, serum VCAM-1 can be used as an indicator for bladder cancer.&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>VCAM-1,Bladder Cancer,Breast Cancer,Biomarkers,Lung Cancer,</keyword>
	<start_page>195</start_page>
	<end_page>198</end_page>
	<web_url>http://ijwph.ir/browse.php?a_code=A-10-1789-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>A.</first_name>
	<middle_name></middle_name>
	<last_name>Zaki Jafar Al-Asady </last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>15300319475328460023862</code>
	<orcid>15300319475328460023862</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Pharmacology and Toxicology Department, Faculty of Pharmacy, University of Kufa, Kufa, Iraq</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>I.</first_name>
	<middle_name></middle_name>
	<last_name>Ali Hussein Al-Hilaly </last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>15300319475328460023863</code>
	<orcid>15300319475328460023863</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Laboratory Investigation Department, Faculty of Science, University of Kufa, Kufa, Iraq</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
